Member Info for The.Italian

keith and others I'm not for a moment suggesting that the money fountain is now appearing on the horizon but it is interesting from the perspective of a possible change of direction to consider the extent of mellons and abonys involvement in the medical cannabidiol and associated areas.i had no knowledge of this before the recent announcement but we have the following points to consider.assuming the proposals go through approximately 20%of regent will be invested in yooya (it could be as much as 25% depending on how you measure it )where the focus apparently is going to be on online promotion of hemp derived products (i am probably simplifying this but that is what it sounds like).15%of yooya is held by FFWD (the repository of the ill fated diabetic boot co) where mellon is the non executive chairman and owns 10.8%of FFWD and abony is the CEO with 9.8%.a year ago FFWD sold its holding in Aphria (a substantial canadian company) as FFWD stated it was committed to the medical cannabis area of activity and Aphria was proposing to enter the recreational area following the legalisation of cannabis in Canada and this area was incompatible with FFWDs status as a guernsey incorporated company.in march of this year FFWD invested £2m in Emmac Life sciences a european medical cannabis company in which mellon holds 8.2% and Abony 7.6%.Emmac has today acquired Green leaf a french hemp based wellness company providing established e-commerce and retail distribution model in France.in January mellon and abony were principal investors (with others) in a 33m$ fundraise for Socati an Oregon based leading provider of THC free full spectrum hemp.within the last day or so Abony has joined the board of Socati.
please bear in mind the some of my descriptions of the companies are how they describe themselves not my personal view of them.
so its pretty clear that mellon and abony have a big interest and indeed large interests in the medical cannabis area.my guess is that they are seeking to expand this significantly in Asia and China to complement their approach to europe and that regent may be the vehicle whereby they do this.this is pure speculation of course and the big problem with CBD /wellness products is not it seems that the market isn't there but rather that this is a very fashionable area with significant competition from many sources.as someone who suffered somewhat in the dotcom bubble i fervently hope that this is not another tulip mania .i do expect further acquisitions in this area quite shortly which will move regents focus further from fortacin and i do not think it an impossibility that we may see a disposal of the rights to fortacin at some point.just speculating of course and time will tell

good man daytrader67!

keith/bothwell only 6 and a half years for me before this particular mast, although it does feel a lot longer.i do however wonder if the likely advent of lorne abony to the board may herald a form of mutiny under which gibson the current captain (or has he really always been the bosun's mate?) has his authority if not formally overturned at least subordinated to abony and could this lead ultimately to corporate keelhauling and a long plank walk? more thoughts on this later.

agreed that socati looks likely.

encouraging!

the approval l was for a very limited field of complicated urinary tract infections this severely limited the amount of income Achaoegen was able to generate.not saying the outcome is of no relevance here but it is a very different area of application.dyor

ivy/ianb i think i am correcting in saying that GLdefinitely confirmed in the conference call that a comparator would be required but i think he ducked the question as to what this might be.not completely sure as i haven't listened back but i suppose its just possible that he does have a good idea but would not wish to dislose it for fear of giving a steer as to what the next steps are going to involve until it has been formally agreed with FDA.i assume that using vanc as the comparator again is unlikely(?) so am wondering what other potential compactors there are.i have no knowledge in this area and there may be many possibilities but if there is actually a limited field would this be be an indication that a HABP trial involving a new comparator field is in contemplation? just speculating and looking for some possible positive clues amongst the wreckage.interested in others views

absolutely nil chance of that I'm afraid.my opinion only of course but its not going to happen.no doubt they are privy to information not in the public domain which would either preclude this for regulatory reasons or more likely for reasons of prudent self interest.

agree with both yours and shrewdeds posts.important to have realistic expectations here.not going to rocket overnight but hoping for a steady rise over time

thanks very much matador.im obliged you.

doggo are you able please to reference exactly which interview you are referring to in you 15.34 post as I'm struggling tofind it..thank you

would it be the case that the target market here is older than the festival/concert audience thus providing a gateway to the introduction into households of more expensive headsets etc and thus in turn encouraging indirectly the uptake by the younger audiences in the festival/concert area?hope that makes sense

looks like extremely good news to me.

touched a nerve perhaps?

why bother with the facts when you have an agenda to fulfil.im genuinely sorry for investors who lose out badly as we all do from time to time but no excuse for misleading posts imo.

ian et al i also listened to the conference call late last night and agree that there were ,or appeared to be,hints at a JV.also i felt lumsden was emphasising the fact that the FDA were encouraging them to resubmit and the that was actually how it had been put rather than just the company's optimistic take on it but who knows.my loss is 90% now so going to stick it out t see what happens.

however this pans out its very hard to see lumsden surviving long.reputations once lost are very hard if not impossible to regain.difficult to see anyone wanting to replace him in current circumstances but impossible to predict what will happen now.thoth2's scenario is certainly plausible although i am hoping it does not end as badly as he predicts.

sorry for the ridiculous break in. posting..Carrying on, at the other extreme the loan notes might never be exercised but the dire conditions for that scenario to happen hardly bear thinking about.on paper also the company can in certain circumstances elect to redeem the notes instead of issuing shares but i suspect this is a paper power only in practice, as the persons in effective control of the company will clearly be the note holders.in practice of course you would expect the notes to be exercised in full at some point when the sp(hopefully)justifies it and that'll most likely be when the interest has accrued to a significant level, so i expect the level of dilution to be very much of the order you have highlighted bignose.it has been very helpful of you to highlight this as it's clearly dilution on a grand scale.you are correct also in highlighting the increased benefits to the note holders through the interest charge if the s/p increases significantly.in fairness i suppose this is simply a function of the gearing effect which the s/p increases automatically brings to the note holders. if we reach s/p 0.75hkd i will probably personally be out but that does not diminish the significant benefits which the note holders stand to gain if things go well.the other side of the coin is i suppose that without this fairly significant cash injection its hard to see how we could have carried on and at least its an amount which should keep us going for a while.fingers crossed that there can be some positive synergy between marketing of fortacin and the yooya platform etc (regulations permitting etc) and as you mentioned we are overdue news on HK.hope we hear something soon.finally i know nothing about CBD and its marketing avenues and prospects.if anyone does have any knowledge or experience in this area I'm sure we would all be interested.

yes i am hoping to see another TR1 shortly which i hope will be a signal for further interest.just my opinion of course.

agreed technical.i think a change of personnel is probably going to happen as current bod do not seem up to it.i do not necessarily blame them for the initial 14th feb situation as they seemed to have followed FDA guidelines so far as we can tell but they do not seen to have got to grips with the situation thereafter and certainly seem have been less than forthcoming in their statements and market guidance since then.this assumes that motif keeps going in its present form and can secure finance which is of course by no means certain .will be continuing to hold as currently 85%down so little point in bailing out now although i have virtually zero expectation now of a positive outcome sorry to say.gla